ProCE Banner Activity

Open Questions: Case Discussions on Optimal Integration of Checkpoint Inhibitors into the Management of Unresectable Stage III NSCLC

Slideset Download
Download this slideset to see how our expert faculty would apply checkpoint inhibitor therapy in the treatment of a series of case patients with unresectable stage III NSCLC, including a frail patient, a patient with delayed recovery following concurrent CRT, and a patient with an actionable mutation.

Released: November 08, 2018

Expiration: November 07, 2019

No longer available for credit.

Share

Faculty

Julie Brahmer

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland